biological characterisation of high risk childhood cancer in children, adolescents and young adults (micchado)

Conditions: Neuroblastoma; Rhabdomyosarcoma; Ewing Sarcoma Family of Tumors; Osteosarcoma; Leukemia; Central Nervous System Tumor

Summary: methodology: prospective, multicentric, open, non-randomised, non-therapeutic, interventional study

to identify and characterise: * meaningful molecular genetic alterations, * meaningful immunological features of high risk childhood, adolescents and young adult cancers, at diagnosis, during patient treatment and follow-up (time dimension).

Eligibility criteria:
inclusion criteria: 1. inclusion within 3 months after diagnosis 2. availability of a cryopreserved tumour sample (primary and/or metastatic and/or lymph nodes) or peripheral blood or bone marrow samples (if invasion more than 30% of lymphoblasts) for leukaemias, obtained at the time of diagnosis during a routine procedure 3. availability of a formalin-fixed paraffin-embedded (ffpe) tumour sample (primary and/or metastasis and/or lymph nodes), obtained at the time of diagnosis during a routine procedure (except for leukaemia patients) 4. age: ≤ 25 years at diagnosis 5. written patient informed consent, or parents or legal representative written informed consent and assent of the child and the adolescent 6. compulsory affiliation to a social security scheme additional inclusion criteria for the study: to avoid multiple sampling for children, adolescents and young adults with cancer, patients already included or to be included in a study with similar analyses and/or objectives might also be included in micchado study and in this case, samples or data might be exchanged on a collaborative basis. cohort 1: * high risk neuroblastoma: - any type of neuroblastoma with mycn amplification, except inss stage 1 - stage 4 neuroblastoma in children older than one year at diagnosis * high risk rhabdomyosarcoma: * foxo1 rearrangement any stage; * and / or n1 ; * and / or metastatic rhabdomyosarcoma * high risk ewing sarcoma: * metastatic ewing sarcoma family of tumours (esft) * localised inoperable ewing sarcoma with primary tumours ≥ 200 ml * high risk osteosarcoma: - metastatic osteosarcoma - localised inoperable osteosarcoma * high risk leukaemia: * secondary acute myeloid leukaemia * biphenotypic acute leukaemia cohort 2: • extra cerebral or cerebral high risk tumours including: * other metastatic sarcomas, * other rare high risk cancers, * high risk renal tumours with surgery after an initial chemotherapy * rhabdoid brain tumours (at/rt) and extra cerebral rhabdoid tumours * high risk or metastatic cancers of unclear histological diagnosis • lymphoblastic leukaemia with high mrd at day 78 (time point 2) • very high risk t-cells acute lymphoblastic leukaemia: * mrd ≥ 10-2 at the end of the induction ; * or mrd ≥ 10-3 at day 78 cohort 3: children, adolescents and young adults, with low/intermediate risk cancers belonging to the following types: • neuroblastoma: - localised, without mycn amplification * localised, inss stage 1, with mycn amplification * stage 4s, in infants (younger than one year at diagnosis), without mycn amplification • rhabdomyosarcoma: * localised, without foxo1 rearrangement • esft: * all non-high risk localised esft • osteosarcoma: * all non-high risk localised osteosarcoma exclusion criteria: main non-inclusion criteria common to all study cohorts: 1) age: patients \> 25 years old at diagnosis 2) absence of patient or parents or legal representative written informed consent 3) patient for whom follow-up by the investigating centre does not appear feasible